Back

ICON4

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial

Date of Publication:

June 21, 2003

Pubmed Link:
https://pubmed.ncbi.nlm.nih.gov/12826431/
Hypothesis:

Will the addition of paclitaxel to platinum chemotherapy prolong overall survival in patients with platinum-sensitive recurrent ovarian cancer?

Control Arm(s):

Carboplatin or cisplatin every 3 weeks for 6-8 cycles

Experimental Arm(s):

carboplatin or cisplatin every 3 weeks for 6-8 cycles

Paclitaxel 175 or 185mg/m2 over 3hrs

Primary End Point:

OS

Inclusion Criteria:

Recurrent platinum-sensitive (>6-12mo) ovarian cancer

Primary treatment contained platinum chemotherapy

Exclusion Criteria:
Results:

Paclitaxel+platinum vs. platinum-only:

median f/u: 42 mos

median OS: 29 vs. 24 months (SS)

1yr PFS: 50% vs. 40% (SS)

CR or PR: 66% vs. 54% (SS)

more alopecia in paclitaxel-platinum arm

more hematologic toxicity in platinum-only arm

Conclusions:

Adding paclitaxel to carboplatin prolongs OS in patients with platinum-sensitive recurrent ovarian cancer.

Reviewer:
Ross Harrison, OTF